Translation of Anticancer Efficacy From Nonclinical Models to the Clinic
Duda, D G
Takimoto, C H
MetadataShow full item record
CitationStroh, M, D G Duda, C H Takimoto, S Yamazaki, and P Vicini. 2014. “Translation of Anticancer Efficacy From Nonclinical Models to the Clinic.” CPT: Pharmacometrics & Systems Pharmacology 3 (8): e128. doi:10.1038/psp.2014.28. http://dx.doi.org/10.1038/psp.2014.28.
AbstractMouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12987402
- HMS Scholarly Articles